Sublingual Melatonin Composition with Valerenic and Carnosic Acids

The patent uses sublingual administration as an intermediary route between oral and parenteral administration. The sublingual mucosa serves as a mediator that allows direct absorption of melatonin into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism, thereby improving bioavailability and reducing onset time compared to conventional oral formulations

The patent replaces the mechanical digestion and absorption process of the gastrointestinal tract with direct mucosal absorption in the sublingual region. This substitution eliminates the need for gastric breakdown and hepatic metabolism, allowing faster and more reliable delivery of melatonin to the systemic circulation

The patent merges melatonin with plant-derived extracts containing specific active compounds (such as valerenic acid from Valeriana and carnosic acid from Rosmarinus officinalis) in defined molar ratios. This combination creates a synergistic effect that enhances therapeutic efficacy for insomnia and inflammatory conditions while reducing the required dosage of each individual component, thereby minimizing side effects

The patent creates a composite pharmaceutical formulation consisting of melatonin combined with plant-derived active ingredients in specific proportions. This composite material leverages the complementary mechanisms of action of its components - melatonin's circadian rhythm regulation and antioxidant effects, combined with the plant compounds' anxiolytic and anti-inflammatory properties - to achieve superior therapeutic outcomes with reduced adverse effects